ClinicalTrials.gg
CompletedNCT02159729Updated Feb 17, 2020Results posted

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

A Phase 2 interventional study of Placebo and ATX-101 (1 mg/cm^2) in Submental Fat and Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 20 sites in 4 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)

Read the detailed description

No study medication was administered in this study.

02

Conditions studied

  • Submental Fat
  • Healthy
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any subject who successfully completed a Kythera-sponsored clinical trial of ATX-101 (06-03, 07-07, 09-15)
  • Signed
  • Willingness to comply with schedule and procedures of the study

Exclusion criteria

Exclusion Criteria:

  • Subjects who have had or are undergoing treatment that may affect the evaluation of the submental area will be excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
205 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants treated with placebo in previous ATX-101 studies

    Drug: Placebo

  • Experimental
    ATX-101 (1 mg/cm^2)

    Participants treated with ATX-101 (1 mg/cm\^2) in previous phase 2 studies

    Drug: ATX-101 (1 mg/cm^2)

  • Experimental
    ATX-101 (2 mg/cm^2)

    Participants treated with ATX-101 (2 mg/cm\^2) in previous phase 2 studies

    Drug: ATX-101 (2 mg/cm^2)

  • Experimental
    ATX-101 (4 mg/cm^2)

    Participants treated with ATX-101 (4 mg/cm\^2) in previous phase 2 studies

    Drug: ATX-101 (4 mg/cm^2)

Interventions

  • DrugPlacebo

    Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

  • DrugATX-101 (1 mg/cm^2)

    Drug page: APIM-containing Peptide ATX-101

    Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

  • DrugATX-101 (2 mg/cm^2)

    Drug page: APIM-containing Peptide ATX-101

    Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

  • DrugATX-101 (4 mg/cm^2)

    Drug page: APIM-containing Peptide ATX-101

    Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)

  2. Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)

  3. Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)

  4. Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)

07

Results

Posted Feb 17, 2020

Participant flow

The objective of this non-treatment, placebo-controlled, 5-year follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study.

Participant flow — Overall Study
MilestoneATX-101 (Deoxycholic Acid) InjectionPlacebo
Started14065
Completed9844
Not completed4221
Withdrew: Adverse event01
Withdrew: Subject's request1310
Withdrew: Lost to follow-up249
Withdrew: Non compliance20
Withdrew: Other unspecified31

Outcome measures

PrimaryPercentage of Participants Maintaining CR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Baseline100.0100.0
Visit 1 (Month 3)93.183.3
Visit 2 (Month 6)94.068.8
Visit 3 (Month 9)94.981.3
Visit 4 (Month 12)94.082.4
Visit 5 (Month 18)95.183.3
Visit 6 (Month 24)89.675.0
Visit 7 (Month 36)80.876.5
Visit 8 (Month 48)85.264.3
Visit 9 (Month 60)71.271.4
PrimaryPercentage of Participants Maintaining PR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Baseline100.0100.0
Visit 1 (Month 3)94.773.3
Visit 2 (Month 6)94.180.0
Visit 3 (Month 9)87.594.4
Visit 4 (Month 12)85.094.4
Visit 5 (Month 18)80.683.3
Visit 6 (Month 24)85.782.4
Visit 7 (Month 36)81.894.1
Visit 8 (Month 48)78.180.0
Visit 9 (Month 60)84.893.3
PrimaryPercentage of Participants Maintaining Composite SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Baseline100.0100.0
Visit 1 (Month 3)84.675.0
Visit 2 (Month 6)82.683.3
Visit 3 (Month 9)82.8100.0
Visit 4 (Month 12)79.371.4
Visit 5 (Month 18)73.171.4
Visit 6 (Month 24)73.183.3
Visit 7 (Month 36)65.285.7
Visit 8 (Month 48)60.983.3
Visit 9 (Month 60)73.983.3
PrimaryPercentage of Participants Maintaining Composite SMFRS 2-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
Up to 60 months from long-term follow-up (LTFU) baseline (the last visit in the previous study)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Baseline100.0100.0
Visit 1 (Month 3)0.00.0
Visit 2 (Month 6)66.7100.0
Visit 3 (Month 9)66.7100.0
Visit 4 (Month 12)100.0100.0
Visit 5 (Month 18)0.0100.0
Visit 6 (Month 24)100.0100.0
Visit 7 (Month 36)100.00.0
Visit 8 (Month 48)100.00.0
Visit 9 (Month 60)100.0100.0

Adverse events

Collected over Up to 60 months from the last visit in the previous study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATX-101 (Deoxycholic Acid) Injection0/140 (0%)3/140 (2.1%)0/140 (0%)
Placebo1/65 (1.5%)3/65 (4.6%)0/65 (0%)
Most frequent serious events
Most frequent serious events
EventATX-101 (Deoxycholic Acid) InjectionPlacebo
Patient died of pancreatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1401/65
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1401/65
HypocalcemiaMetabolism and nutrition disorders0/1401/65
Thyroid cancerEndocrine disorders0/1401/65
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1400/65
Asymptomatic cystic thyroid massEndocrine disorders1/1400/65
Third degree heart blockCardiac disorders1/1400/65

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean46.8 ± 8.8648.2 ± 9.9447.2 ± 9.22
Sex: Female, Male
Sex: Female, Male(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Female11143154
Male292251
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American224
White13156187
More than one race7512
Unknown or Not Reported000
Baseline weight (kg)
Baseline weight (kg)(kilogram (kg))ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean80.64 ± 16.68385.93 ± 15.98382.32 ± 16.610
08

Study locations

20 sites
  • Total Skin & Beauty Dermatology Center
    Birmingham, Alabama 35205, United States
  • Clinical Testing Center Beverly Hills
    Beverly Hills, California 90210, United States
  • Mokusiga, Inc
    Beverly Hills, California 90212, United States
  • Plastic & Reconstructive Surgery
    San Francisco, California 94115, United States
  • Dermatology Institute of DuPage Medical Group in Naperville
    Naperville, Illinois 60563, United States
  • Skin Care Physicians
    Chestnut Hill, Massachusetts 02467, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Body Aesthetic Research Center
    Saint Louis, Missouri 63141, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Research Across America
    Plano, Texas 75093, United States
  • Mei-Heng Tan
    Sydney, New South Wales 2000, Australia
  • Skin Centre, AHC House
    Benowa, Queensland 4217, Australia
  • Southeast Dermatology Belmont Specialist Centre
    Carina Heights, Queensland 4152, Australia
  • T/AS Dermatology Institute of Victoria
    South Yarra, Victoria 3141, Australia
  • Niagara Falls Dermatology & Skin Care
    Niagara Falls, Ontario L2E 7H1, Canada
  • Institute of Cosmetic & Laser Surgery
    Oakville, Ontario L6J 7W5, Canada
  • Toronto Cosmetic Skin Surgery Centre
    Toronto, Ontario M4V 1R1, Canada
  • Cosmetic Dermatology on Bloor
    Toronto, Ontario M5S 3B4, Canada
  • The Dermatology Centre
    Salford, Manchester M6 8HD, United Kingdom
  • Cranley Clinic, Harcout House
    London, W1G OPN, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2014
First posted
Jun 10, 2014
Start
Feb 2009
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Feb 17, 2020
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02159729
Responsible party
Sponsor
First posted
Jun 10, 2014
Start date
Feb 2009
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Feb 17, 2020
Last update
Feb 17, 2020

Study contacts

Frederick Beddingfield, III, MD, PhD
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion